58.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$62.88
Aprire:
$57.91
Volume 24 ore:
32.42M
Relative Volume:
3.66
Capitalizzazione di mercato:
$293.24B
Reddito:
$42.09B
Utile/perdita netta:
$14.65B
Rapporto P/E:
17.69
EPS:
3.2833
Flusso di cassa netto:
$10.11B
1 W Prestazione:
-5.11%
1M Prestazione:
-27.54%
6M Prestazione:
-50.87%
1 anno Prestazione:
-53.36%
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
![]()
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2025-03-13 | Aggiornamento | Kepler | Hold → Buy |
2025-03-03 | Downgrade | Stifel | Buy → Hold |
2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
2024-05-30 | Iniziato | Goldman | Buy |
2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
2024-01-23 | Iniziato | Morgan Stanley | Overweight |
2024-01-16 | Ripresa | UBS | Neutral |
2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
2023-10-02 | Iniziato | Argus | Buy |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2022-06-28 | Downgrade | UBS | Neutral → Sell |
2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
2022-01-25 | Downgrade | Liberum | Hold → Sell |
2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
2021-01-15 | Iniziato | Deutsche Bank | Buy |
2020-09-29 | Iniziato | Berenberg | Hold |
2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
2020-05-11 | Downgrade | UBS | Buy → Neutral |
2020-05-04 | Iniziato | Cowen | Market Perform |
2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
2018-12-11 | Ripresa | Jefferies | Hold |
2018-10-09 | Iniziato | Guggenheim | Buy |
2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
Where Will Eli Lilly Be in 5 Years? - The Motley Fool
Is Novo Nordisk Stock a Buy After its Collapse? - Morningstar
Eli Lilly and Novo Nordisk: Obesity Drug Coverage in Medicare Not a Straight Path - Morningstar
Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market - Yahoo Finance
Why Novo Nordisk Stock Dipped on Thursday - Yahoo Finance
Novo Nordis Share Price | NYSE: NVO Stock - Investing.com UK
NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - Finansavisen
Novo Nordisk shares plunge after obesity drug trial - The Irish Independent
Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus.com
Novo Nordisk A/S Sponsored ADR Class B to Host Earnings Call - ACCESS Newswire
NVO Stock Quote Price and Forecast - CNN
META_TITLE_QUOTE - Yahoo Finance
Repare Surprises On Earnings; California Resources Falls Short - Evrim Ağacı
Why weight-loss drugs are the top target of Medicare price negotiations - Equities News
Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):